Contents

Search

sorafenib (Nexavar)

Trademark: Nexavar, FDA approved 2005 Indications: - advanced kidney cancer (renal cell carcinoma) - gastrointestinal stromal tumor - hepatocellular carcinoma [3] - metastatic thyroid carcinoma [2,4] - may be of benefit for induction & maintenance of AML in patients < 60 years of age [5] Adverse effects: - fatigue - hypertension - rash, hands, feet [3] - thrombosis, thrombotic microangiopathy [6] - cardiotoxicity - hypothyroidism Laboratory: - sorafenib in serum/plasma Mechanism of action: - tyrosine kinase inhibitor - VEGFR: VEGFR1, VEGFR2, VEGFR3, PDGFR - Raf kinases Manufacturer: Bayer/Onyx

Interactions

drug adverse effects of tyrosine kinase inhibitor(s)

General

antineoplastic tyrosine kinase inhibitor pharmaceutical angiogenesis inhibitor (angiostatic agent)

Database Correlations

PUBCHEM cid=216239

References

  1. Prescriber's Letter 13(2): 2006 Detail-Document#: 220215 (subscription needed) http://www.prescribersletter.com
  2. Physician's First Watch, June 3, 2013 David G. Fairchild, MD, MPH, Editor-in-Chief Massachusetts Medical Society http://www.jwatch.org - Brose MS et al Sorafenib in locally advanced or metastatic patients with radioactive iodine-refractory differentiated thyroid cancer: The phase III DECISION trial. 2013 ASCO Meeting Abstract J Clin Oncol 31, 2013 (suppl; abstr 4) http://meetinglibrary.asco.org/content/112795-132
  3. Medical Knowledge Self Assessment Program (MKSAP) 16, 17 American College of Physicians, Philadelphia 2012, 2015
  4. FDA News Release: Nov. 22, 2013 FDA approves Nexavar to treat type of thyroid cancer http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm376443.htm
  5. O'Neil A, Short NJ AML: TKI Sorafenib Added to '7+3' Equals EFS Benefit. The multiple kinase inhibitor targets several different pathways important for AML development and maintenance. MedPage Today. Jan 11, 2018 https://www.medpagetoday.com/reading-room/asco/hematologic-malignancies/70405 - Rollig C, et al The addition of sorafenib to standard AML treatment results in a substantial reduction in relapse risk and improved survival. Updated results from long-term follow-up of the randomized- controlled Soraml Trial. American Society of Hematology (ASH) 2017; Abstract 721.
  6. NEJM Knowledge+ Nephrology/Urology